Full Press Release Details
Medical Enhances Scientific Advisory Board with World Renowned Interventional Radiologists
Advisory Board Expanded with Additions of Global Medical Pioneers and Distinguished Thought Leaders
Mass., January 21, 2021 - Microbot Medical Inc. (Nasdaq: MBOT) continues to enhance its thought leadership capabilities
with the addition of several new Scientific Advisory Board (SAB) members: Stephen B. Solomon, MD, a board-certified radiologist
with clinical expertise in Interventional Radiology with a focus in Tumor Ablation; Ajay K. Wakhloo, MD PhD FAHA, an internationally
recognized expert in acute stroke therapy and the isolation of intracranial aneurysms and arteriovenous malformations; Gal Yaniv,
MD, PhD, an endovascular neurosurgeon and leading authority on Artificial Intelligence; Dmitry J. Rabkin, MD, PhD, FSIR, a vascular
and Interventional Radiology Specialist; and Ziv Neeman, MD, a vascular and interventional radiology clinician and researcher
with a wide array of expertise, particularly in the field of navigation systems for minimally invasive image-guided interventional
we continue to develop and perfect our novel technologies, it remains critical that we also attract extraordinary capabilities
throughout the organization - management, Board of Directors and Scientific Advisory Board - to leverage their combined expertise
to achieve Microbot Medical's objectives," commented Harel Gadot, CEO, President and Chairman. "We are expecting
a higher level of activity in the next year, including significant clinical and regulatory milestones, so our ability to attract
leading talent and capitalize on their successes should enable us to maintain a competitive advantage and be at the forefront
of developing innovative technologies to address the healthcare industry's unmet medical needs."
| Gal Yaniv, MD, PhD is a founder and the Chief Medical Officer at Aidoc, contributing his expertise and knowledge to help in the continuing development of advanced, healthcare grade AI. He is currently the Director, Endovascular Neurosurgery unit at Sheba - Tel HaShomer hospital. A double graduate (M.D, PhD, cum laude on both) of the Technion - Israel Institute of Technology, Dr. Yaniv completed his radiology residency at Sheba, Tel HaShomer hospital as well as diagnostic neuroradiology fellowship at Yale School of Medicine and endovascular neurosurgery fellowship at Mount Sinai Hospital. He has published numerous scientific publications focusing on basic science, radiology and public health, including a recent publication at the New England Journal of Medicine, and has presented in various scientific conferences worldwide. As a "Talpiot" alumni, he participates in the "Talpiot Medical Leadership Program" at Tel HaShomer Hospital. | ||
| Dmitry J. Rabkin, MD, PhD, FSIR is a Vascular and Interventional Radiology Specialist, who is currently the Assistant Professor of Radiology at the Harvard Medical School and Assistant Chief of the Division of Interventional Radiology at the Brigham and Women's Hospital. Previously, he was a Clinical Director and Chief of the Division of Interventional Radiology at the Beth Israel Deaconess Medical Center, HMS, where he completed his residency in Diagnostic Radiology and a fellowship in Vascular and Interventional Radiology. He graduated from the First Moscow Medical School. Based on his achievements and contributions to the specialty, Dr. Rabkin has been elected to Fellowship of the Society of Interventional Radiology. Dr. Rabkin has been recognized as a Castle Connolly Top Doctor and Boston Magazine Top Doctor since 2016 for his professional qualifications, reputation and clinical skills in the field of Interventional Radiology. | ||
| Ajay K. Wakhloo, MD PhD FAHA is certified by the American Board of Radiology in Neuroradiology and Diagnostic Radiology, and he currently serves as Chief of Neurointerventional Radiology and Professor at TUFTS University School of Medicine. Prior to Tufts, he was a tenured Professor of Radiology, Neurology and Neurosurgery and the Director, Division NeuroImaging and Intervention (NII) in the Department of Radiology, University of Massachusetts Medical School. Earlier in his career, Dr. Wakhloo was a tenured Professor of Radiology, Neurological Surgery and Biomedical Engineering in the Department of Radiology at the University of Miami, Miller School of Medicine. He received both his medical degree and Ph.D. from the University of Mainz, Germany and completed his Internship and Residency in Internal Medicine at the University of Mainz. His training was continued at the University of Freiburg, Germany in diagnostic and interventional Neuroradiology. He also completed fellowships in Neurosurgery at the University of Freiburg and Endovascular Neurosurgery at SUNY Buffalo, as well as Research Fellowships in Neurological Surgery at Barrow Neurological Institute and in Neurosurgery at SUNY Buffalo. |
new SAB members join a renowned panel of neurosurgeons and thought leaders in robotic medical technologies, including Prof. Moshe
Shoham. Prof. Shoham is the co-founder of Microbot Medical and founder of Mazor Robotics. The Company believes that the combined
contributions from their diverse sets of expertise will help drive development of next generation robotic endoluminal surgery
devices targeting the minimally invasive surgery space.
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological
platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).
Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes
for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical
is available at http://www.microbotmedical.com.
pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to
future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities
for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to
statements that contain words such as "will," "believes," "plans," "anticipates,"
"expects" and "estimates") should also be considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary
closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY
and SCS, the outcome of its studies to evaluate LIBERTY, SCS and other existing and future technologies, uncertainty in the results
of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic,
need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing
Microbot Medical can be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed
with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical
disclaims any intent or obligation to update these forward-looking statements, except as required by law.